CSI Market
Sign In | Register

Adhera Therapeutics Inc (ATRX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ATRX Annual Cash Flow →
The table below presents a historical view of Adhera Therapeutics Inc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2023)
6 Months 		(Mar 31 2023) (Dec 31 2022) (Sep 30 2022) (Jun 30 2022)
Operating Activities
Income0.27
Depreciation & amortization0.00
Amortization of Other Assets1.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Ongoing Project0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt-0.08
Non Cash Research And Development Expense-
Non Cash Expense For Fair Value Of Warrants Issued In Connection With Amendments To Securities Purchase Agreements-
Gain Loss On Disposition Of Property-
Net Gain On Settlement Of Liabilities-
Change In Fair Value Of Price Adjustable Warrants And Subscription Investment Units-
Non Cash Gain On Settlement Of Liabilities-
Non Cash Interest Expense-
Non Cash Financing Costs-
Change In Fair Value Of Stock Reserved For Issuance To Settle Liabilities-
Embedded Derivative Gain Loss On Embedded Derivative Net-
Increase Decrease In Deferred Rent-
Common Shares Issued For Third Party Services-
Loss On Settlement With Issuance Of Common Shares-
Loss On Note Settlement With Issuance Of Preferred Shares-
Common Shares Issued For Settlement-
Accrued Interest Expense-
Derivative Gain Loss On Derivative Net-2.46
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-0.09
Increase (Decrease) in Accrued Liabilities0.09
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.02
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.50
Discontinued operations0.00
Net Cash flow from Operating Activities-0.63
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.81
Other borrowing transactions-0.06
Long-term debt - borrowings-0.10
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Sales Of Common Shares And Warrants Net-
Proceeds From Issuance Of Notes Payable And Warrants Gross-
Proceeds From Issuance Of Notes Payable And Warrants-
Proceeds Frpm Net Insurance Financing-
Proceeds From Net Insurance Financing-
Proceeds From Sales Of Series C Preferred Shares And Warrants Net-
Payments For Insurance Financing-
Proceed From Convertible Note Related Party-
Loan Fees-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.65
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.63
Total Cash Flow0.03
4 historic quarters locked

Sign in to unlock the full Adhera Therapeutics Inc cash flow history.

Sign In Create Free Account

About Adhera Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-23-042138

Figures are derived from filed reports and may be restated. Historical data is subject to revision.